{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T19:01:02.110505+00:00","company":{"ticker":"IDXG","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"fbe724804e4d4881b7ddc618e1aba5f886320fe8","cik":1054102,"ticker":"IDXG","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2026-04-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$22.8 million and $25.0 million, respectively","period_text":"fourth quarter and fiscal year ended December 31, 2025","report_date":"2026-03-30","result_type":"reported_results","revenue_text":"$9.2 million and $38.7 million, respectively"},"claim":"INTERPACE BIOSCIENCES, INC. reported fourth quarter and fiscal year ended December 31, 2025 results: revenue $9.2 million and $38.7 million, respectively, net income $22.8 million and $25.0 million, respectively.","evidence_excerpt":"stated in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nInterpace\nBiosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results ● Q4\n and FY Revenue of $9.2 million and $38.7 million ● Q4\n and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting\n adjustment) ●","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-014654","anchor_url":"https://secwatch.observer/filing/0001493152-26-014654#claim-fbe724804e4d4881b7ddc618e1aba5f886320fe8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/0001493152-26-014654-index.htm"},{"fact_type":"earnings_release","fact_key":"948f25fed192c3f3b9d7fcadbe1ce4c6deb55226","cik":1054102,"ticker":"IDXG","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.6 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$10.3 million"},"claim":"INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $10.3 million, net income $0.6 million.","evidence_excerpt":"stated in such filing. \n\n--- EX-99.1 () ---\n\nEX-99.1 2 ex99-1.htm Exhibit\n99.1 Interpace\nBiosciences Announces First Quarter 2024 Financial and Business Results ● Q1\n Revenue of $10.3 million; a 4% increase year-over-year ● Q1\n Test volume up 10% year over year to record levels PARSIPPANY,\nNJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018465","anchor_url":"https://secwatch.observer/filing/0001493152-24-018465#claim-948f25fed192c3f3b9d7fcadbe1ce4c6deb55226","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224018465/0001493152-24-018465-index.htm"}]}